Radiopharm Theranostics Limited (ASX: RAD) - Share Price
Current share price for RAD : $0.011 0.001 (8.33%)+
Radiopharm Theranostics Limited (RAD) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It operates as a clinical stage radiotherapeutics organisation developing a platform of radiopharmaceutical products for diagnostic and therapeutic use in areas of unmet medical need. The development pipeline consists of platform technologies that include peptides, small molecules, and monoclonal antibodies for cancer applications.
RAD General Information +
| ASX Code | RAD |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 47 |
| RAD Share Price | $0.011 |
| Day High | $0.012 |
| Day Low | $0.010 |
| Last Close | $0.012 |
| RAD Share Price Movement | $0.00 ( 8.33% ) |
Prices as at 16:35, 14 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Radiopharm Theranostics Limited (RAD) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Radiopharm Theranostics Limited (RAD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Radiopharm Theranostics Limited (RAD) price-sensitive announcements
RAD - Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company listed on the
Radiopharm Theranostics Limited (RAD)
31 Jul 2026 | 11:19 AM
31 Jul 2026 | 11:19 AM
RAD - Reinstatement to Quotation
Radiopharm Theranostics Limited, trading under the ticker RAD on the Australian Securities
Radiopharm Theranostics Limited (RAD)
24 Jul 2026 | 5:21 PM
24 Jul 2026 | 5:21 PM
RAD - RAD completes A$12.5 M placement and launches A$6 M SPP
Radiopharm Theranostics Limited announced the successful completion of a A$12.5 million ca
Radiopharm Theranostics Limited (RAD)
24 Jul 2026 | 5:20 PM
24 Jul 2026 | 5:20 PM
RAD - Suspension from Quotation
Radiopharm Theranostics Limited (ASX: RAD) announced that its securities will be suspended
Radiopharm Theranostics Limited (RAD)
24 Jul 2026 | 9:14 AM
24 Jul 2026 | 9:14 AM
Radiopharm Theranostics Limited (RAD) Recent ASX Announcements
RAD Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | -$1.40 | 22.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | -$1.10 | -29.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$34.27 | -$1.60 | -83.90% | 0.00 | 0.00 | 0.00% | 0.0% |
RAD Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| CSL Limited (CSL) | $66,301M | 0.1108 | -0.1238 | 0.0167 | 14.8450 | 16.9424 | 16.6645 | 3.22% | 2.62% | 2.73% |
| Clinuvel Pharmaceuticals Limited (CUV) | $479M | 0.0287 | 0.0000 | 0.0000 | 13.2312 | 0.0000 | 0.0000 | 0.53% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $3,117M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Radiopharm Theranostics Limited (RAD) | $52M | -0.8386 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,736M | -1.3893 | 0.0000 | -0.1436 | 0.0000 | 278.5479 | 325.2408 | 0.00% | 0.00% | 0.00% |
RAD Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Riccardo Canevari | Chief Executive Officer, Managing Director | 13 Sep 2021 |
| Mr Paul Alex Hopper | Executive Chairman, Founder, Executive Director | 11 Feb 2021 |
| Mr Ian Turner | Non-Executive Director | 1 Apr 2021 |
| Ms Hester Larkin | Non-Executive Director | 3 Feb 2022 |
| Mr Noel Donnelly | Non-Executive Director | 1 Oct 2024 |
| Mr Bruce Goodwin | Non-Executive Director | 19 Nov 2025 |
Radiopharm Theranostics Limited (RAD) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 25 Mar 2026 | TURNER, Ian | Buy | Indirect Shares | 730,000 | $0.019 | $13,870.000 |
| 30 Oct 2025 | CANEVARI, Riccardo | Buy | Indirect Shares | 1,500,000 | $0.025 | $37,500.000 |
| 23 May 2025 | TURNER, Ian | Buy | Indirect Shares | 3,000,000 | $0.029 | $87,000.000 |
See all changes in directors' interest & trades for Radiopharm Theranostics Limited (RAD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
RAD Management
| Name | Position |
|---|---|
| Dimitris Voliotis | Chief Medical Officer |
| Amritha Sushil | Joint Company Secretary |
| Nathan Kim -liung Jong | Joint Company Secretary |
RAD Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Radiopharm Theranostics Limited (RAD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 282,958,513 (12.12%) | Lantheus Omega, LLC |
| 145,362,288 (7.30%) | Regal Funds Management Pty Ltd |
| 174,583,414 (6.90%) | JPmorgan Chase & Co. and its affiliates |
| 149,221,428 (6.90%) | Paul Hopper |
RAD Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 16 September 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
